COVID-19 Research Paper Volume 13, Issue 13 pp 16904—16921

Prognostic and immunological value of ATP6AP1 in breast cancer: implications for SARS-CoV-2

Associated clinicopathological factors and promoter methylation levels of ATP6AP1 in BC. (A) ATP6AP1 levels in various pathological substages of BC in GEPIA. (B) ATP6AP1 levels in different disease stages of BC in UALCAN. (C) The correlation between lymph node metastasis and ATP6AP1 expression in BC. (D) ATP6AP1 promoter methylation profiles of different sample types. (E) ATP6AP1 promoter methylation levels of different BC disease stages. (F) ATP6AP1 promoter methylation levels of different major subclasses of BC. *P **P ***P

Figure 5. Associated clinicopathological factors and promoter methylation levels of ATP6AP1 in BC. (A) ATP6AP1 levels in various pathological substages of BC in GEPIA. (B) ATP6AP1 levels in different disease stages of BC in UALCAN. (C) The correlation between lymph node metastasis and ATP6AP1 expression in BC. (D) ATP6AP1 promoter methylation profiles of different sample types. (E) ATP6AP1 promoter methylation levels of different BC disease stages. (F) ATP6AP1 promoter methylation levels of different major subclasses of BC. *P < 0.05, **P < 0.01, ***P < 0.001.